NCT01767766View on ClinicalTrials.gov

Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 7, 2013

Primary Completion Date

February 28, 2018

Study Completion Date

February 28, 2018

Conditions

Non-Hodgkin's LymphomaChronic Lymphocytic LeukemiaPeripheral T-Cell LymphomaHodgkin's Lymphoma

Interventions

DRUG

TGR-1202

TGR-1202 Daily Oral Dose

Trial Locations (7)

10019

TG Therapeutics Trial Site, New York

27710

TG Therapeutics Trial Site, Durham

34232

TG Therapeutics Trial Site, Sarasota

37203

TG Therapeutics Trial Site, Nashville

45242

TG Therapeutics Trial Site, Cincinnati

53226

TG Therapeutics Investigational Trial Site, Milwaukee

07601

TG Therapeutics Trial Site, Hackensack

All Listed Sponsors

collaborator

SCRI Development Innovations, LLC

OTHER

lead

TG Therapeutics, Inc.

INDUSTRY

NCT01767766 - Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies | Biotech Hunter | Biotech Hunter